<div id="readability-page-1"><div>By Megan Cheah Shares of CSPC Pharmaceutical Group fell sharply after the Chinese company inked a multibillion-dollar deal with pharmaceutical giant AstraZeneca for its long-acting obesity drug. The Hong Kong-listed stock dropped as much as 13% before closing 10% lower at 9.60 Hong Kong dollars, equivalent to US$1.23. The decline was its biggest daily percentage loss in nearly a year. CSPC said earlier Friday that it entered an obesity drug agreement with AstraZeneca that would give the U.K.-based pharmaceutical company rights outside China to its clinical-ready long-acting obesity asset and three other preclinical assets. The Chinese company will receive US$1.2 billion upfront and be eligible for up to US$17.3 billion in development and sales milestone payments. Analysts at Macquarie Capital viewed Friday's drop as profit-taking after what they said was CSPC's largest outlicensing deal. The deal cements CSPC's status as one of China's most innovative biopharmaceutical companies, alongside peer Hengrui Pharmaceuticals, at a time when large Chinese pharmaceutical companies are pivoting toward innovation, the analysts said. The new agreement also builds on a previous deal with AstraZeneca, which granted the British company global rights to a preclinical inhibitor for a US$100 million upfront payment in 2024, the analysts said. CSPC's research and development efforts are &#34;clearly bearing fruit,&#34; they said. Friday's share-price decline came after the stock gained 26% this year and could be an entry opportunity for investors, Macquarie Capital said, reiterating its outperform rating and HK$12.40 target price. Write to Megan Cheah at megan.cheah@wsj.com (END) Dow Jones Newswires01-30-26 0454ET</div></div>

石药集团

石药集团的股价在与阿斯利康达成一项数十亿美元的肥胖药物交易后下跌了 10%，创下近一年来最大的单日跌幅。根据分析师的说法，股价在获利了结中下跌至 9.60 港元（1.23 美元）。石药集团将获得 12 亿美元的预付款，并可能在里程碑付款中赚取高达 173 亿美元。尽管股价下跌，分析师们仍将其视为潜在的买入机会，维持 “跑赢大盘” 的评级，目标价为 12.40 港元

石药集团在与阿斯利康达成协议后，股价因可能的获利回吐而下跌